arGEN-X News
Most Popular arGEN-X Story
arGEN-X gins $13.6M in new funds for mAB work
The Dutch antibody developer arGEN-X has garnered $13.6 million in a Series A, which will be used to develop its antibody platform and create a slate of mAb candidates for development. The deal was... Read more...
Latest Headlines
- September 10, 2009
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
